Results 121 to 130 of about 53,515 (238)
Summary Background and objectives Systemic treatment of cutaneous melanoma has changed since 2011, with clinical studies demonstrating improved outcomes. This analysis evaluated whether this improvement is evident in a real‐world cohort, focusing on overall survival (OS) and relapse‐free survival (RFS).
Lena Nanz +7 more
wiley +1 more source
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Ipilimumab is a novel FDA-approved recombinant human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 and has been used to treat patients with metastatic melanoma. Immune-related neurological adverse effects include inflammatory myopathy,
Kamiya-Matsuoka, Carlos +4 more
core +1 more source
The CheckMate 743 trial established nivolumab and ipilimumab as the standard first-line treatment for unresectable pleural mesothelioma. However, optimal management following disease progression after a durable response to dual immunotherapy remains ...
Illaa Smesseim, MD +2 more
doaj +1 more source
Cynomolgus Toxicology Signals with Ipilimumab and Nivolumab Combination.
Cynomolgus Toxicology Signals with Ipilimumab and Nivolumab Combination.
Mark J. Selby (3110964) +13 more
core +1 more source
Summary Background Recent therapeutic advances, such as tebentafusp, may prolong survival of metastatic uveal melanoma (mUM) patients. Early detection of metastases during follow‐up (FU) may be clinically relevant; however, FU remains non‐standardized.
Susanne Dugas‐Breit +10 more
wiley +1 more source
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma +7 more
wiley +1 more source
Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer +11 more
wiley +1 more source
Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato +4 more
wiley +1 more source
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma +36 more
wiley +1 more source
ABSTRACT Immune checkpoint inhibitors (ICIs) are now standard of care for most advanced solid tumors. While effective, they are associated with immune‐related adverse events (irAEs), including rare autonomic complications. We present a patient with metastatic lung adenocarcinoma receiving nivolumab and ipilimumab who developed reflex syncope with ...
Ashley Bouzon +3 more
wiley +1 more source

